Gianluca D. C.
- Country
- Italy
- Department
- 3202: Oncologia Medica
Research Overview
- Safety and Efficacy Evaluation of RO7759065 with Atezolizumab in Patients with Locally Advanced or Metastatic Solid Tumors
- Phase I Study of OKI-219 Monotherapy and in Combination with Endocrine or HER2-Targeted Therapy in Advanced Solid Tumors and Breast Cancer
- Phase 1 Dose Escalation and Cohort Expansion Study of Anti-PD-1 Monoclonal Antibody TSR-042 in Advanced Solid Tumors
Data & Insights
Has run more than one trial at 80 of 178 partner sites.
Specializations
Targeted Cancer Therapies
This investigator focuses on evaluating novel targeted therapies, particularly for patients with KRAS mutations and HER2-positive cancers. Their research encompasses innovative treatment approaches for various advanced solid tumors.
- KRAS G12C mutation therapies
- HER2-targeted combination treatments
- Advanced solid tumor interventions
Immunotherapy Research
The investigator specializes in studying immunotherapy combinations, including research on PD-1 inhibitors and novel immune checkpoint modulators for treating various cancer types.
- Combination immunotherapy approaches
- Advanced cancer immunotherapy
- Novel immune checkpoint inhibitors
Specific Cancer Types
Their research portfolio includes studies on multiple specific cancer types, with particular emphasis on non-small cell lung cancer, breast cancer, and gastrointestinal cancers.
- Metastatic solid tumors
- Renal cell carcinoma
- Glioblastoma
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.